Adial Pharmaceuticals (ADIL) Common Equity (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Common Equity of $3.7 million for Q1 2026, down 29.55% sequentially from $5.3 million in Q4 2025, and up 74.79% YoY from $2.1 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Common Equity (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Common Equity for 10 years, with the latest figure at $3.7 million in Q1 2026.
- Quarterly Common Equity rose 74.79% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 74.79% YoY) and the FY2025 annual result came in at $5.3 million, up 29.7% from the prior year.
- Common Equity fell to $3.7 million in Q1 2026 per ADIL's latest filing, from $5.3 million in the prior quarter.
- Over five years, Common Equity peaked at $10.7 million in Q1 2022 and troughed at $1.4 million in Q1 2023.
- A 5-year average of $4.7 million and a median of $4.3 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 86.55% in 2023, then surged 325.16% in 2024.
- Over 5 years, Common Equity stood at $3.3 million in 2022, then climbed by 24.63% to $4.1 million in 2023, then declined by 0.38% to $4.1 million in 2024, then climbed by 29.7% to $5.3 million in 2025, then declined by 29.55% to $3.7 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $3.7 million, $5.3 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | Adial Pharmaceuticals | 28.42 Mn | 28.42 Mn | - | -38.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.72 Mn |
| Dec 31, 2025 | 5.28 Mn |
| Sep 30, 2025 | 4.51 Mn |
| Jun 30, 2025 | 5.59 Mn |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | 4.07 Mn |
| Sep 30, 2024 | 5.88 Mn |
| Jun 30, 2024 | 4.28 Mn |
| Mar 31, 2024 | 6.12 Mn |
| Dec 31, 2023 | 4.08 Mn |
| Sep 30, 2023 | 2.34 Mn |
| Jun 30, 2023 | 3.32 Mn |
| Mar 31, 2023 | 1.44 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Sep 30, 2022 | 5.41 Mn |
| Jun 30, 2022 | 7.96 Mn |
| Mar 31, 2022 | 10.71 Mn |
| Dec 31, 2021 | 3.51 Mn |
| Sep 30, 2021 | 7.20 Mn |
| Jun 30, 2021 | 4.83 Mn |